Utama › Leukemia Limfositik Kronik
Kajian klinikal Leukemia Limfositik Kronik sedang mengambil peserta di AS
120 kajian untuk Leukemia Limfositik Kronik sedang mengambil peserta di lokasi seluruh Amerika Syarikat.
Bandar dengan paling banyak kajian
- Boston, MA31 kajian
- Columbus, OH28 kajian
- Durham, NC27 kajian
- Washington, DC22 kajian
- Seattle, WA20 kajian
- Rochester, MN19 kajian
- New York City, NY18 kajian
- Houston, TX17 kajian
- Baldwin Park, CA16 kajian
- Milwaukee, WI15 kajian
- Cincinnati, OH14 kajian
- Chicago, IL14 kajian
- Nashville, TN13 kajian
- Jacksonville, FL11 kajian
- Philadelphia, PA11 kajian
- Atlanta, GA11 kajian
- Dallas, TX10 kajian
- Portland, OR10 kajian
- Salt Lake City, UT10 kajian
- Kansas City, MO10 kajian
- San Diego, CA10 kajian
- Pittsburgh, PA10 kajian
- Denver, CO9 kajian
- Charlotte, NC9 kajian
- Miami, FL9 kajian
- St. Louis, MO8 kajian
- Los Angeles, CA8 kajian
- Omaha, NE8 kajian
- Winston-Salem, NC8 kajian
- Queens, NY8 kajian
- Des Moines, IA8 kajian
- Tampa, FL8 kajian
- Cleveland, OH8 kajian
- Minneapolis, MN8 kajian
- Clifton, NJ7 kajian
- Cedar Rapids, IA7 kajian
- Mountain View, CA7 kajian
- Aurora, CO7 kajian
- Fort Wayne, IN7 kajian
- Detroit, MI7 kajian
Mengikut negeri
- Alabama7 kajian
- Arizona15 kajian
- Arkansas4 kajian
- California33 kajian
- Colorado17 kajian
- Connecticut4 kajian
- Delaware4 kajian
- Florida34 kajian
- Georgia16 kajian
- Idaho4 kajian
- Illinois17 kajian
- Indiana12 kajian
- Iowa10 kajian
- Kansas6 kajian
- Kentucky7 kajian
- Louisiana6 kajian
- Maine6 kajian
- Maryland23 kajian
- Massachusetts33 kajian
- Michigan12 kajian
- Minnesota29 kajian
- Mississippi5 kajian
- Missouri13 kajian
- Montana7 kajian
- Nebraska8 kajian
- Nevada6 kajian
- New Hampshire3 kajian
- New Jersey13 kajian
- New Mexico3 kajian
- New York26 kajian
- North Carolina34 kajian
- Ohio43 kajian
- Oklahoma4 kajian
- Oregon16 kajian
- Pennsylvania22 kajian
- Rhode Island6 kajian
- South Carolina5 kajian
- South Dakota3 kajian
- Tennessee17 kajian
- Texas38 kajian
- Utah10 kajian
- Virginia12 kajian
- Washington26 kajian
- Wilayah Columbia4 kajian
- Wisconsin19 kajian
Kajian yang dikemas kini baru-baru ini
Teks kajian rasmi (Bahasa Inggeris)
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 110 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05724121Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Mengambil pesertaFasa 1
Sehingga umur 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT01853631Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Mengambil pesertaFasa 3
Umur 65 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07321652Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06863402Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07582432Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT03516617A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06542250Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT04269902A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT05645107A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06943872Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
Mengambil pesertaFasa 2
Umur 75 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07685717A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05006716A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07277231A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06846671A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06697184A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06973187Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 110 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT00923507Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Mengambil pesertaFasa 2
Umur 18 hingga 85 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT03986034A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06136559Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT06784167Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT01087333A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Mengambil pesertaFasa 4
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07218341Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT07648264Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.